Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report

Abstract Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression‐free survival are good.

Bibliographic Details
Main Authors: Elizabete Pumpure, Eva Dručka, Dana Kigitoviča, Raimundas Meškauskas, Sergejs Isajevs, Ineta Nemiro, Agnija Rasa, Evija Olmane, Tatjana Zablocka, Pēteris Alberts, Simona Doniņa
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Clinical Case Reports
Subjects:
ECHO‐7 virus
melanoma
oncology
oncolytic virus
Rigvir
uterine cervix
Online Access:https://doi.org/10.1002/ccr3.2928

Internet

https://doi.org/10.1002/ccr3.2928

Similar Items